Ocular Therapeutix Inc Asset Resilience Ratio
Ocular Therapeutix Inc asset resilience ratio. Ocular Therapeutix Inc (OCUL) has an Asset Resilience Ratio of 0.00% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Ocular Therapeutix Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Ocular Therapeutix Inc (2012–2017)
Asset resilience ratio of Ocular Therapeutix Inc from 2012 to 2017. This chart shows how Ocular Therapeutix Inc's Asset Resilience Ratio has changed over time. See Ocular Therapeutix Inc (OCUL) financial flexibility to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Ocular Therapeutix Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Ocular Therapeutix Inc assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Ocular Therapeutix Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Ocular Therapeutix Inc Industry Peers by Asset Resilience Ratio
Compare Ocular Therapeutix Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Ocular Therapeutix Inc Asset Resilience Ratio by Year (2012–2017)
Ocular Therapeutix Inc asset resilience ratio by year from 2012 to 2017. The table below shows the annual Asset Resilience Ratio data for Ocular Therapeutix Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | $0.00 | $55.43 Million | -- |
| 2016-12-31 | 46.98% | $35.21 Million | $74.94 Million | -20.36pp |
| 2015-12-31 | 67.34% | $74.28 Million | $110.31 Million | +19.46pp |
| 2014-12-31 | 47.88% | $37.44 Million | $78.19 Million | +47.56pp |
| 2013-12-31 | 0.31% | $60.00K | $19.15 Million | +0.08pp |
| 2012-12-31 | 0.24% | $60.00K | $25.29 Million | -- |
About Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as wel… Read more